Trial · NCT01416220
Lithium Versus Paroxetine in Major Depression
NCT01416220, Phase 4, Withdrawn, Nova Scotia Health Authority
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lithium Versus Paroxetine in Major Depression. Trials, record NCT01416220. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01416220
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lithium Versus Paroxetine in Major Depression
- NCT number
- NCT01416220
- Status
- Withdrawn
- Phases
- Phase 4
- Enrollment
- 0 participants, actual
- Lead sponsor
- Nova Scotia Health Authority
- Conditions
- Major Depressive Disorder
- Interventions
- Lithium, Paroxetine
- First posted
- 2011-08-12
- Last updated
- 2024-09-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Montgomery Asberg Depression Rating Scale (MADRS) | Assessed after 6 weeks of treatment | The primary outcome measure will be reduction in the score on the Montgomery Asberg Depression Rating Scale (MADRS), which has become the standard outcome tool in clinical trials for assessing symptoms of depression. Response will be defined as 50% reduction in MADRS Remission will be defined as MADRS ≤ 12. |
| Secondary | The Young Mania Rating Scale (YMRS) | Assessed after 6 weeks of treatment | This is a standard outcome tool used to assess mania. |
| Secondary | The Clinical Global Impression (CGI) | Assessed after 6 weeks of treatment | The Clinical Global Impression (CGI)is a scale used to measure overall symptom severity, treatment response, and treatment efficacy in patients with mood disorders. |
| Secondary | The Columbia Suicide Classification Scale | Assessed over 6 weeks of treatment. | The Columbia Suicide Classification Scale, used in the FDA analysis of pediatric antidepressants, has become a standard tool used in clinical depression trials and will be used to monitor changes in suicide risk or self-harm weekly. |
| Secondary | Barnes Akathisia Rating Scale (BARS) | Assessed over 6 weeks of treatment | Barnes Akathisia Rating Scale (BARS): The BARS is a very brief clinical assessment for the presences of akathisia. Akathisia secondary to antidepressants has been associated with increased suicidality. The inclusion of the BARS will serve to delineate akathisia from psychomotor agitation as part of treatment -emergent mixed symptoms. |
| Secondary | Treatment -emergent symptom checklist and questionnaire | Assessed over 6 weeks of treatment | This checklist and questionnaire will be used to capture a potential range of treatment emergent mixed symptoms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01416220
GET https://conductscience.org/api/trials/v1/NCT01416220/registered